Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
Trial details
- Registry ID
- NCT06465108
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Canvuparatide
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismNCT06465108 | MBX Biosciences | Phase 2 | Completed | 2025-05-23Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |